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 Angiomotin (Amot) was originally identi-
fi ed as an interacting protein of extracellular 
angiostatin (1), but it is also localized intra-
cellularly in the cytoplasm, the lamellipodia 
of migrating cells, and the tight junction of 
epithelial cells. Accordingly, the biochemi-
cal property and functional analysis of Amot 
is likely not directly linked to angiostatin. 
Together with homologous AmotL1 and 
AmotL2, they represent the angiomotin fam-
ily (2) that is present only in vertebrates (3). 
The Amot gene is transcribed into two alter-
natively spliced transcripts that are translated 
into a 130-kD long form (Amot-p130) and a 
80-kD short form (Amot-p80, which lacks 
the N-terminal part present in Amot-p130) 
(4). Because of several motifs and domains 
known to mediate protein-protein interactions 
and the identifi cation of an increasing number 
of interacting partners (5–8), Amot proteins 
are generally believed to act as scaffold pro-
teins to coordinate the functional integration 
of several proteins (Fig. 1). 
The Hippo pathway was originally iden-
tifi ed in the fl y as a signaling pathway that 
is also conserved in humans (9). It consists 
of upstream regulators, central core kinase 
complexes, and downstream effectors Yes-
associated protein (YAP) and transcriptional 
coactivator with PDZ-binding motif (TAZ), 
which act as transcriptional coactivators pri-
marily for the TEA domain (TEAD) family 
of transcriptional factors. The YAP or TAZ 
(YAP/TAZ)-TEAD complex mediates a tran-
scriptional program of hundreds of genes 
(such as CTGF, Cyr61, AXL, and BIRC5, 
which encodes Survivin) to promote cell 
proliferation and inhibit apoptosis. By sens-
ing cell-cell contact and organ size, the up-
stream regulators activate the kinase cascade 
to mediate phosphorylation of YAP and TAZ, 
resulting in their cytoplasmic sequestration or 
proteasome degradation. As such, the Hippo 
pathway primarily restricts the functional 
amount of the YAP/TAZ-TEAD complex in 
the nucleus. Because of the increasing impor-
tance of the Hippo pathway in diverse human 
cancers (such as the observed overexpression 
of TAZ and YAP therein), several laboratories 
identifi ed interacting proteins of YAP/TAZ, 
including the Amot proteins (10–12), in which 
Amot proteins functioned as negative regula-
tors of YAP/TAZ through direct interaction 
through the PPXY (where P indicates Pro; X, 
any amino acid; and Y, Tyr) motifs of Amot 
proteins and WW domains of YAP/TAZ to ei-
ther sequester YAP/TAZ in the cytoplasm or 
target it to the tight junction. Consistent with 
this notion as negative regulators, knockdown 
of Amot proteins increased the expression of 
target genes such as CTGF, which overcame 
cell contact inhibition, and induced epithelial-
mesenchymal transition (EMT).
In the study by Yi et al. in this issue (13), 
collaborative efforts orchestrated by the Kis-
sil laboratory have revealed an unexpected 
and seemingly controversial role of Amot in 
positively regulating YAP in cell prolifera-
tion and cancer development. To address the 
physiological role of Amot in vivo, the team 
investigated the role of Amot in two experi-
mental settings. The fi rst was looking at its 
role in porphyrinogenic hepatotoxin DDC 
(3,5-diethoxycarbonyl-1,4-dihydrocolli-
dine)–induced proliferation of biliary epithe-
lial cells (BECs) characterized by cytokeratin 
19 (CK19+) abundance, which is referred to 
as the oval cell response and generally be-
lieved to be involved in liver cancer devel-
opment. In this injury model, the Amot gene 
was selectively deleted in the liver by cross-
ing Amot conditional knockout mice with 
albumin-Cre transgenic mice (AmotKO). Be-
cause the albumin-Cre allele mediates gene 
deletion at early stages of liver development, 
AmotKO mice are expected to have the gene 
deleted in both BECs and hepatocytes. Liver-
specifi c AmotKO mice were phenotypically 
indistinguishable from littermate controls, 
suggesting that Amot is dispensable for 
normal liver development. However, when 
AmotKO mice were subjected to DDC injury, 
the oval cell response (the dramatic increase 
in CK19+ cells) was substantially suppressed, 
suggesting that Amot is required for injury-
induced proliferative expansion of BECs. 
However, this suppression was incomplete, 
suggesting that there may be functional com-
pensation by AmotL1 or AmotL2. In their 
second approach, the role of Amot was inves-
tigated in hepatocyte proliferation and cancer 
development in mice with liver-specifi c dele-
tion of NF2. NF2 encodes Merlin, a tumor 
suppressor, and its liver-specifi c knockout in 
mice resulted in the expansion of the CK19+ 
ductal cell population, increased liver weight, 
and eventually formation of hepatic tumors. 
Both Amot and NF2 were deleted in the liver 
by crossing mice fl oxed for these two genes 
with albumin-Cre mice. In contrast to NF2 
single-knockout mice, NF2/Amot double-
knockout (DKO) mice showed reduced inci-
dence of CK19+ cell proliferation and hepa-
tocarcinoma, indicating that Amot promotes 
hepatic ductal cell proliferation and tumor 
formation in response to NF2 deletion. The 
partial suppression of the oncogenic phe-
notype may also result from the compensa-
tory function of AmotL1 or AmotL2. These 
results are consistent with an earlier study 
from Kissil’s laboratory showing that Amot 
is required for the tumorigenicity of NF2-null 
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 The Hippo pathway regulates cell proliferation and apoptosis during develop-
ment, tissue regeneration, and carcinogenesis. Nuclear translocation of the tran-
scription factors Yes-associated protein (YAP) and transcriptional coactivator 
with PDZ-binding motif (TAZ) and their subsequent interaction with TEA domain 
(TEAD) transcriptional factors program pro-proliferative and antiapoptotic tran-
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a transcriptional cofactor of the YAP-TEAD complex to facilitate proliferation of 
biliary epithelial cells and cancer development of the liver either in response to 
tissue injury or in the absence of the tumor suppressor Merlin. These seemingly 
controversial results highlight that our understanding of Amot proteins in the 
Hippo pathway is so far limited.
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Schwann cells (5). Also consistent is that the 
abundance of Amot was increased in NF2-
KO liver tumors as well as in multiple clinical 
samples of human schwannomas. These ex-
periments clearly established an in vivo role 
for Amot in positively regulating cell prolif-
eration and cancer development in response 
to tissue injury or NF2 deletion.
This raises the fundamental question: 
What is the mechanistic basis underlying 
this different role of Amot? The authors 
validated the interaction of Amot with YAP 
and revealed that an LPXY (L, Leu) mo-
tif preceding the known functional PPXY 
motif also participated in the interaction 
with WW domains of YAP. They provided 
biochemical evidence that Amot-YAP in-
teraction not only suppressed the negative 
regulation by the Hippo core kinase cascade 
but also promoted nuclear translocation of 
YAP. Transcriptional profi ling indicated that 
a subset of genes regulated by YAP may be 
dependent on Amot, and the nuclear Amot-
YAP-TEAD complex was observed at the 
promoter region of some YAP target genes, 
such as ApoE, AREG, and TGFB1, but not 
CTGF. The functional relevance of those 
genes whose transcription is dependent on 
the Amot-YAP-TEAD complex has yet to be 
validated both in vitro and in vivo.
This study not only reveals a different role 
and mode of action of Amot in vivo but also 
raises new questions that await investiga-
tion. For example, is the functional outcome 
of Amot-YAP interaction regulated differ-
entially (such as by posttranslational modi-
fi cations or through interaction with other 
proteins) in those earlier studies compared 
with this study? What dictates whether the 
Amot-YAP complex will be targeted to the 
tight junction, sequestered in the cytoplasm, 
or translocated into the nucleus? What is 
the clinical consequence of increased abun-
dance of Amot (and AmotL1 or AmotL2) in 
human cancers? Further insight is likely to 
come in the near future.
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Fig. 1. Through protein-protein interaction, 
Amot may promote the nuclear translocation 
and transcriptional activity of YAP. (A) Sche-
matic illustration of Amot and its interacting 
partners, either direct (green) or indirect (blue). 
Human Amot consists of 1084 residues. The 
N-terminal region contains two PPXY motifs 
and one PPXY-like LPTY (T, Thr) motif that in-
teract with WW domains in YAP or AIP4 (atro-
phin 1–interacting protein). The central portion 
has coiled-coil regions that interact with Merlin 
or RICK1 [a member of the Rho guanosine tri-
phosphatase (GTPase)-activating protein fam-
ily, also called ARHGAP17], whereas the C-
terminal type II PDZ-binding motif interacts with 
the PDZ domains of Patj [protein associated 
with C. elegans Lin-7 protein 1 (PALS1)–associ-
ated tight junction (TJ) protein], enabling Amot 
to act as a scaffold protein in cell proliferation, 
migration, and cell junction assembly. Kibra, 
kidney and brain protein (also known as WW 
domain–containing protein 1); Rac1, Ras-relat-
ed C3 botulinum toxin substrate 1; Syx, RhoA 
guanine exchange factor; Rho, a GTPase.(B) A 
model of Hippo-Amot cross-talk. YAP shuttles 
between the cytoplasm and the nucleus (pro-
cess 1). Within the nucleus, YAP functions as a 
transcriptional coactivator of TEAD. The YAP-
TEAD complex promotes the transcription of 
many genes that encode pro-proliferative and 
antiapoptotic proteins (2). Upon cell-cell con-
tact or when an organ reaches its physiologi-
cal size, upstream regulators activate the Hippo 
core kinase cascade to phosphorylate YAP at 
multiple sites (3), which sequesters YAP in the 
cytoplasm and can prime it for proteosomal degradation (4). Earlier studies show that Amot func-
tions as a negative regulator of YAP by inducing its cytoplasmic retention or targeting it to cell 
junctions (5). Amot appears to also function as a positive regulator of YAP by promoting its nuclear 
translocation (6), where Amot may act as a cofactor to promote the transcription of a subset of 
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